cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00006985
title: A Pilot Trial of Daily Oral ZD1839 (Iressa) With Standard Doses of Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006993
title: An open-label, non comparative, two arm phase II trial of ZD1839 (Iressa) in patients with hormone-insensitive (ER and PgR negative) or hormone-resistant (ER and/or PgR positive) metastatic or inoperable locally advanced breast cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007005
title: A phase I/II trial to evaluate the tolerability, the maximum tolerated dose, dose limiting toxicity and activity of ZD1839 in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007015
title: A phase Ib/II study to evaluate the maximum tolerated dose, dose limiting toxicity and activity of ZD1839 in combination with capecitabine and irinotecan (Capeiri) as second-line or third-line therapy after failure IV or oral fluoropyrimidine plus oxaliplatin +/- previous IV or oral fluoropyrimidine therapy in patients with advanced colorectal cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007016
title: A Phase Ib/II study to evaluate the maximum tolerated dose, dose limiting toxicity and activity of ZD1839 in combination with 5-FU/FA and irinotecan (FOLFIRI) as second line or third line therapy after failure of IV or oral fluoropyrimidine plus oxaliplatin +/- previous IV or oral fluoropyrimidine therapy in patients with advanced colorectal cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007014
title: A phase Ib/II study to evaluate the maximum tolerated dose, dose limiting toxicity and activity of ZD1839 in combination with weekly 24H infusion  5-FU/FA and oxaliplatin (FUFOX) as well as the efficacy of ZD1839 and ZD1839 with fufox as second line or third line therapy after failure of IV or oral fluoropyrimidine plus irinotecan +/- previous IV or oral fluoropyrimidine therapy in patients with advanced colorectal cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006995
title: A phase I/II trial to evaluate ZD1839 (Iressa) and epirubicin combination therapy as second line treatment in patients with advanced metastatic breast cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007029
title: A Randomized, Double-Blind, Single-dose, Five-Treatment, Placebo-Controlled, Cross-Over Study to Assess the Cardiovascular Safety (Including QT/QTc Intervals) of Two Dose Levels (One Therapeutic and One Supra-therapeutic) of Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) and a Supra-therapeutic Dose of Glycopyrronium Metered Dose Inhaler (GP MDI) in Healthy Adult Volunteers, Compared with Moxifloxacin (400 mg Open-Label) as the Positive Control.\n

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007006
title: AN OPEN, RANDOMISED, NON COMPARATIVE PHASE II TRIAL OF DOCETAXEL (TAXOTERE) IN COMBINATION WITH ZD1839 (IRESSA) AND DOCETAXEL ALONE AS SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006981
title: Dose-Response of Effects on GM-CSF and Leucocyte Progenitors in Asthmatic Patients after Repeated Inhalation of Budesonide via Turbuhaler.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007044
title: An attempt to find clinically equivalent doses of budesonide administered from a metered dose inhaler or as a suspension for nebulisation.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006983
title: Oxis Turbuhaler (formoterol), Accolate (zafirlukast) or placebo as add on treatment to Pulmicort Turbuhaler(budesonide) in asthmatic patients on inhaled steroids.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007008
title: A Phase II double blind, randomised, multicentre trial comparing Gefitinib (ZD1839) versus placebo as maintenance therapy after 1st line chemotherapy for patients with hormone receptor negative (ER-/PR-) metastatic breast cancer (MAREN)

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007055
title: A double-blind, randomized, placebo-controlled multicenter steroid sparing study in patients with chronic steroid dependent asthma

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007011
title: A phase II trial to evaluate ZD1839 (Iressa) as second line treatment in patients with loco-regional or metastatic relapse of cervical cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006982
title: A double-blind, randomised study of high dose reducing budesonide (Pulmicort) versus maintenance budesonide in moderate to severe asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007001
title: An open label non comparative phase II trial of ZD1839 (Iressa) in combination with docetaxel (TAXOTERE) in patients with advanced or metastatic non small cell lung cancer failing or unsuitable for platinum based chemotherapy

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007003
title: A phase II trial of ZD1839 (Iressa) in combination with oxaliplatin and capecitabine as first-line chemotherapy in patients with advanced colorectal cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5281/zenodo.6807764
title: Data from: Manipulation of Miniature and Microminiature Bodies on a Harmonically Oscillating Platform by Controlling Dry Friction

description: Data from the paper "Manipulation of Miniature and Microminiature Bodies on a Harmonically Oscillating Platform by Controlling Dry Friction" https://doi.org/10.3390/mi12091087 Currently used nonprehensile manipulation systems that are based on vibrational techniques employ temporal (vibrational) asymmetry, spatial asymmetry, or force asymmetry to provide and control a directional motion of a body. This paper presents a novel method of nonprehensile manipulation of miniature and microminiature bodies on a harmonically oscillating platform by creating a frictional asymmetry through dynamic dry friction control. To theoretically verify the feasibility of the method and to determine the control parameters that define the motion characteristics, a mathematical model was developed, and modeling was carried out. Experimental setups for miniature and microminiature bodies were developed for nonprehensile manipulation by dry friction control, and manipulation experiments were carried out to experimentally verify the feasibility of the proposed method and theoretical findings. By revealing how characteristic control parameters influence the direction and velocity, the modeling results theoretically verified the feasibility of the proposed method. The experimental investigation verified that the proposed method is technically feasible and can be applied in practice, as well as confirmed the theoretical findings that the velocity and direction of the body can be controlled by changing the parameters of the function for dynamic dry friction control. The presented research enriches the classical theories of manipulation methods on vibrating plates and platforms, as well as the presented results, are relevant for industries dealing with feeding, assembling, or manipulation of miniature and microminiature bodies.
description: This research was funded by a grant (No. S-MIP-19-64) from the Research Council of Lithuania
DOI: 10.5281/zenodo.6807763
title: Data from: Manipulation of Miniature and Microminiature Bodies on a Harmonically Oscillating Platform by Controlling Dry Friction

description: Data from the paper "Manipulation of Miniature and Microminiature Bodies on a Harmonically Oscillating Platform by Controlling Dry Friction" https://doi.org/10.3390/mi12091087 Currently used nonprehensile manipulation systems that are based on vibrational techniques employ temporal (vibrational) asymmetry, spatial asymmetry, or force asymmetry to provide and control a directional motion of a body. This paper presents a novel method of nonprehensile manipulation of miniature and microminiature bodies on a harmonically oscillating platform by creating a frictional asymmetry through dynamic dry friction control. To theoretically verify the feasibility of the method and to determine the control parameters that define the motion characteristics, a mathematical model was developed, and modeling was carried out. Experimental setups for miniature and microminiature bodies were developed for nonprehensile manipulation by dry friction control, and manipulation experiments were carried out to experimentally verify the feasibility of the proposed method and theoretical findings. By revealing how characteristic control parameters influence the direction and velocity, the modeling results theoretically verified the feasibility of the proposed method. The experimental investigation verified that the proposed method is technically feasible and can be applied in practice, as well as confirmed the theoretical findings that the velocity and direction of the body can be controlled by changing the parameters of the function for dynamic dry friction control. The presented research enriches the classical theories of manipulation methods on vibrating plates and platforms, as well as the presented results, are relevant for industries dealing with feeding, assembling, or manipulation of miniature and microminiature bodies.
description: This research was funded by a grant (No. S-MIP-19-64) from the Research Council of Lithuania
DOI: 10.25934/pr00008059
title: Systemic availability of budesonide inhaled as suspension aerosol with metered dose inhaler and as dry powder with Turbuhaler. Prestudy

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008061
title: Comparison of aerosol delivery from terbutaline sulphate and budesonide Turbuhaler(R) in healthy subjects.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008068
title: Comparative effects of single doses of inhaled budesonide and D5159 on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to methacholine

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008069
title: A Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Intravenous Doses of ICI 182,780 (ZD9238) in Healthy Male Volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008070
title: Post-study observation of subjects who have reached the primary endpoint under repeated oral doses of 500 \xb5g roflumilast in study BY217/FHP035.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008072
title: Pharmacokinetics of 250 \xb5g, 375 \xb5g and 500 \xb5g roflumilast in children and adolescents with mild to moderate asthma and healthy adult subjects \u2013 an open, one-period, three parallel group design with repeated oral doses of once daily roflumilast for 14 days

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008073
title: An Evaluation of the Effects of Roflumilast on Cardiac Repolarization, Pharmacokinetics, Safety, and Tolerability in Healthy Volunteers

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008075
title: Safety and tolerability of the new phosphodiesterase inhibitor (B9302-107) administered to healthy  male volunteers as ascending single oral doses

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.